Jubilant Pharmova’s wholly owned subsidiary Jubilant Pharma, today announced that its subsidiary Jubilant Generics (JGL) received a communication from the USFDA through which the regulatory agency intimated that pursuant to its January 25 to February 2, 2024 audit of JGL’s Solid dosage manufacturing facility at Roorkee, India, it has determined the inspection classification of the facility as Voluntary Action Indicated (VAI).
| Subscribe To Our Free Newsletter |
